COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Stem Cell Mobilization by G-CSF Post Myocardial Infarction to Promote Myocyte Repair

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00394498
Recruitment Status : Unknown
Verified October 2006 by University of Ottawa.
Recruitment status was:  Recruiting
First Posted : November 1, 2006
Last Update Posted : November 1, 2006
Canadian Institutes of Health Research (CIHR)
Information provided by:
University of Ottawa

Brief Summary:

Eighty-six patients with heart attacks will be identified at our hospital. Post heart attack we will assess heart function, blood flow to the heart, and heart cell function. We will assess these parameters using nuclear cardiology scans that are used in everyday cardiology practice. The patients will then be divided into 2 groups. One group will receive a medication called G-CSF and the other group will receive a placebo. We will give this drug (1-2ml) for 4 days beneath the skin. We will take the patients blood during this time and measure how the drug affected their blood. The patients will all have the nuclear cardiology tests again in 6 weeks and 6 months to see how their heart is functioning. As well, they will have a six month angiogram. All the patients will otherwise receive optimal care from their Cardiologist. They will be seen at 6, 12, 24, and 52 weeks to assess them clinically.

This study will test the effects of G-CSF on the heart function of patients who have had a heart attack. It is a medication that that has been shown in an animal model to improve heart function after a heart attack. It is a medication that has been used for many years to treat patients with cancers and to increase the number of cells donated by healthy bone marrow donors. It has no serious side effects. It works by increasing the number of a person’s own stem cells in the blood. Stem cells are special cells that are present in our bodies that have the ability to form new cells. It had been thought that the heart could not make new cells after it has been damaged. Other investigators have shown that this might not be the case. It is now thought that after an injury, stem cells from the bone marrow can transform into cells of the injured tissue. Therefore, we are trying to increase the number of stem cells in the circulation with G-CSF so as to increase repair in the heart after it has been damaged. This strategy has never been tried in human beings and if successful could greatly reduce death and suffering from heart disease.

Condition or disease Intervention/treatment Phase
Myocardial Infarction Drug: Granulocyte Colony Stimulating Factor Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Stem Cell Mobilization by G-CSF by Granulocyte Colony Stimulating Factor Post Myocardial Infarction to Promote Myocyte Repair
Study Start Date : September 2005
Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Primary Outcome Measures :
  1. 6 month Left ventricular ejection fraction

Secondary Outcome Measures :
  1. 6 week left ventricular ejection fraction
  2. 6 week myocardial FDG-PET uptake
  3. 6 week myocardial Ammonia-PET perfusion
  4. 6 week/month left ventricular diastolic volume
  5. 6 week/month left ventricular systolic volume

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Large anterior wall ST elevation AMI defined by: Post AMI LVEF less than 45% as assessed by echocardiography. It is standard practice at our institution to obtain echocardiograms on such patients before day 4 post AMI.
  2. Age between 40 -75 years
  3. Angiographically patent infarct related artery (IRA) with TIMI 3 flow with no significant stenosis (>70% diameter stenosis in non-intervened upon arteries or >30% in arteries that had PTCA), no dissection or visible thrombus, and considered at low risk for re-occlusion by the Cardiologist performing the coronary angiography. In patients who have undergone PTCA, this assessment will be none on a post PTCA angiogram. This will be the majority of patients.
  4. Eligible for treatment with G-CSF within the 5 days Post AMI.

Exclusion Criteria:

  1. Prior STEMI
  2. Patients with regional wall motion abnormalities in the non-infarct region
  3. Prior CABG or need for CABG
  4. Patients with significant valve disease; defined as stenosis or regurgitation graded as greater than moderate (2+).
  5. Patients with clinically apparent, concurrent infection, requiring intravenous antibiotics
  6. Patients who are or could be pregnant
  7. Patients with another etiology of LV dysfunction (known/suspected non ischemic cardiomyopathy, previous anthracycline therapy, known ethanol abuse (greater than 6 oz. ethanol/day on a regular basis).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00394498

Layout table for location contacts
Contact: Chris A Glover, MD 613-761-4119

Layout table for location information
Canada, Ontario
University of Ottawa Heart Institute Recruiting
Ottawa, Ontario, Canada, K1Y 4W7
Sponsors and Collaborators
University of Ottawa
Canadian Institutes of Health Research (CIHR)
Layout table for investigator information
Principal Investigator: Chris A Glover, MD Ottawa Heart Institute Research Corporation
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00394498    
Other Study ID Numbers: 135287
First Posted: November 1, 2006    Key Record Dates
Last Update Posted: November 1, 2006
Last Verified: October 2006
Keywords provided by University of Ottawa:
Myocardial Infarction
Stem Cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic